Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trialShelagh B. Coutts, Robert Simister, Sandeep Ankolekar et al.|The Lancet|2024Cited by 134
Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct OutcomesEric E. Smith, Thomas Töll, Ashkan Shoamanesh et al.|Stroke|2024Cited by 10
Safety and tolerability of Rinvecalinase Alfa (DM199) for acute ischemic stroke (ReMEDy1)Bruce Campbell, Dennis Cordato, Helen M. Dewey et al.|International Journal of Stroke|2025Cited by 3